Showing results (361-370 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|March 5, 2026
The impact of HIV stigma and discrimination on HIV testing, antiretroviral treatment, and viral suppression in Africa: a pooled analysis of population-based surveysCarla M Doyle, Salome Kuchukhidze, James Stannah, et al.
The Lancet. HIV|June 4, 2023
Barriers and facilitators to HIV pre-exposure prophylaxis for cisgender and transgender women in the UKIsabelle Whelan, Sophie Strachan, Vanessa Apea, et al.
The Lancet. HIV|February 2, 2024
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept studyJoseph J Eron, Susan J Little, Gordon Crofoot, et al.
The Lancet. HIV|March 27, 2024
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding studyElizabeth D Lowenthal, Jennifer Chapman, Rachel Ohrenschall, et al.
The Lancet. HIV|January 31, 2024
Trends in COVID-19 admissions and deaths among people living with HIV in South Africa: analysis of national surveillance dataWaasila Jassat, Caroline Mudara, Lovelyn Ozougwu, et al.
The Lancet. HIV|July 26, 2023
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trialAnchalee Avihingsanon, Hongzhou Lu, Chee Loon Leong, et al.
The Lancet. HIV|April 11, 2024
Non-suppressible viraemia during HIV-1 therapy: a challenge for cliniciansAndrés Esteban-Cantos, Rocío Montejano, Adriana Pinto-Martínez, et al.
The Lancet. HIV|November 3, 2023
The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysisValentina Cambiano, Alec Miners, Fiona C Lampe, et al.
The Lancet. HIV|October 13, 2023
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysisTom Loosli, Stefanie Hossmann, Suzanne M Ingle, et al.
The Lancet. HIV|March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
Pageof 79